Search Results

There are 31477 results for: content related to: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia

  1. You have free access to this content
    Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue 9, September 1999, Pages: 1149–1159, Camilleri, Mayer, Drossman, Heath, Dukes, Mcsorley, Kong, Mangel and Northcutt

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00610.x

  2. You have free access to this content
    Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue s2, May 1999, Pages: 39–47, G. Audolfsson, O. Bayguinov, T. Yamamoto, G.T. Somogyi, W.H. Schraut, K.M. Sanders and A.J. Bauer

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00004.x-i2

  3. You have free access to this content
    Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue 11, November 1999, Pages: 1419–1427, Jones, Holtmann, Rodrigo, Ehsanullah, Crompton, Jacques and Mills

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00678.x

  4. You have free access to this content
    A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

    Alimentary Pharmacology & Therapeutics

    Volume 14, Issue 1, January 2000, Pages: 23–34, Bardhan, Bodemar, Geldof, Schütz, Heath, Mills and Jacques

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.2000.00684.x

  5. You have free access to this content
    Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue s2, May 1999, Pages: 77–82, A.W. Mangel and A.R. Northcutt

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00010.x

  6. You have free access to this content
    Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome

    Alimentary Pharmacology & Therapeutics

    Volume 14, Issue 7, July 2000, Pages: 869–878, Thumshirn, Coulie, Camilleri, Zinsmeister, Burton and Van Dyke

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.2000.00786.x

  7. You have free access to this content
    Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications

    Alimentary Pharmacology & Therapeutics

    Volume 17, Issue 8, April 2003, Pages: 1021–1030, U. Ladabaum

    Article first published online : 9 APR 2003, DOI: 10.1046/j.1365-2036.2003.01545.x

  8. You have free access to this content
    Review article: clinical pharmacology of alosetron

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue s2, May 1999, Pages: 70–76, M.D. Gunput

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00009.x

  9. You have free access to this content
    Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans

    Alimentary Pharmacology & Therapeutics

    Volume 16, Issue 2, February 2002, Pages: 225–233, B. Kuo, M. Camilleri, D. Burton, B. Viramontes, S. McKinzie, G. Thomforde, M. K. O'Connor and B. H. Brinkmann

    Article first published online : 18 JAN 2002, DOI: 10.1046/j.1365-2036.2002.01144.x

  10. You have free access to this content
    Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers

    Alimentary Pharmacology & Therapeutics

    Volume 16, Issue 5, May 2002, Pages: 993–1002, C. H. M. Clemens, M. Samsom, G. P. Van Berge Henegouwen, M. Fabri and A. J. P. M. Smout

    Article first published online : 27 APR 2002, DOI: 10.1046/j.1365-2036.2002.01252.x

  11. You have free access to this content
    Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

    Alimentary Pharmacology & Therapeutics

    Volume 14, Issue 6, June 2000, Pages: 775–782, Houghton, Foster and Whorwell

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.2000.00762.x

  12. You have free access to this content
    Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors

    Alimentary Pharmacology & Therapeutics

    Volume 17, Issue 2, January 2003, Pages: 279–287, M. Simrén, L. Simms, D. D'Souza, H. Abrahamsson and E. S. Björnsson

    Article first published online : 16 JAN 2003, DOI: 10.1046/j.1365-2036.2003.01399.x

  13. You have free access to this content
    Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome

    Alimentary Pharmacology & Therapeutics

    Volume 12, Issue 9, September 1998, Pages: 849–855, M. Delvaux, D. Louvel, J.-P. Mamet, R. Campos-Oriola and J. Frexinos

    Article first published online : 25 DEC 2001, DOI: 10.1046/j.1365-2036.1998.00375.x

  14. You have free access to this content
    The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme

    Alimentary Pharmacology & Therapeutics

    Volume 25, Issue 3, February 2007, Pages: 317–322, P. TENNIS, E. ANDREWS, P. HICKMAN, D. MILLER, K. HOLLIS and S. COOK

    Article first published online : 8 JAN 2007, DOI: 10.1111/j.1365-2036.2006.03198.x

  15. You have free access to this content
    Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome

    Alimentary Pharmacology & Therapeutics

    Volume 13, Issue s2, May 1999, Pages: 31–38, P.P.A. Humphrey, C. Bountra, N. Clayton and K. Kozlowski

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.1999.00003.x-i2

  16. You have free access to this content
    Review article: intestinal failure

    Alimentary Pharmacology & Therapeutics

    Volume 24, Issue 1, July 2006, Pages: 19–31, S. LAL, A. TEUBNER and J. L. SHAFFER

    Article first published online : 16 JUN 2006, DOI: 10.1111/j.1365-2036.2006.02941.x

  17. You have free access to this content
    The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

    Alimentary Pharmacology & Therapeutics

    Volume 16, Issue 7, July 2002, Pages: 1357–1366, E. A. Mayer, S. Berman, S. W. G. Derbyshire, B. Suyenobu, L. Chang, L. Fitzgerald, M. Mandelkern, L. Hamm, B. Vogt and B. D. Naliboff

    Article first published online : 25 JUL 2002, DOI: 10.1046/j.1365-2036.2002.01287.x

  18. You have free access to this content
    Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors

    Alimentary Pharmacology & Therapeutics

    Volume 20, Issue 2, July 2004, Pages: 223–230, K. M. Koch, B. W. Corrigan, J. Manzo, C. D. James, R. J. Scott, A. G. Stead and K. E. Kersey

    Article first published online : 25 JUN 2004, DOI: 10.1111/j.1365-2036.2004.02031.x

  19. You have free access to this content
    The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain – a randomized, double-blind, placebo-controlled, crossover trial

    Alimentary Pharmacology & Therapeutics

    Volume 19, Issue 10, May 2004, Pages: 1123–1130, J. Bautista, H. Fullerton, M. Briseno, H. Cui and R. Fass

    Article first published online : 29 APR 2004, DOI: 10.1111/j.1365-2036.2004.01941.x

  20. You have free access to this content
    A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme

    Alimentary Pharmacology & Therapeutics

    Volume 24, Issue 5, September 2006, Pages: 869–878, D. MILLER, L. BENNETT, K. HOLLIS, P. TENNIS, S. COOK and E. ANDREWS

    Article first published online : 16 AUG 2006, DOI: 10.1111/j.1365-2036.2006.03031.x